On January 11, several listed companies announced positive developments. Defu Technology (301511.SZ) disclosed that it recently signed a Letter of Intent for Acquisition with Anhui Huiru Technology Co., Ltd. and its actual controller, Wang Sun'gen. The company plans to acquire no less than a 51% equity stake in Huiru Technology through a combination of cash purchase and capital increase. Upon completion of the transaction, Huiru Technology will become a controlled subsidiary. Huiru Technology is primarily engaged in the R&D, production, and sales of various high-performance electrolytic copper foils, with its main products including lithium battery copper foil and electronic circuit copper foil. As of the announcement date, Huiru Technology's annual production capacity for electrolytic copper foil stands at 20,000 tons. This transaction represents a merger within the same industry. With Defu Technology's current capacity utilization nearing saturation, this acquisition is expected to enable rapid capacity expansion in the short term to meet growing downstream demand. Huadong Medicine (000963.SZ) announced that DR10624, a long-acting triple-target agonist independently developed by its controlled subsidiary, Doer Biologics, has been included in the Breakthrough Therapy Designation list, with its intended indication being severe hypertriglyceridemia. DR10624 is a globally pioneering long-acting trispecific agonist targeting FGF21R, GCGR, and GLP-1R. Phase II clinical study results have demonstrated its excellent efficacy in reducing TG levels, comprehensively regulating pro-inflammatory lipid profiles, and rapidly and deeply eliminating liver fat. It is important to note that the drug still requires completion of subsequent clinical trials and must obtain review and approval from the National Medical Products Administration before it can be marketed, and drug development carries inherent risks and uncertainties. Shandong Xiantan Group Co.,Ltd. (002746.SZ) reported that in December 2025, the company achieved sales revenue of 529 million yuan from its chicken products, with a sales volume of 55,100 tons. These figures represent year-on-year increases of 9.41% and 6.76%, respectively. Jiamei Food Packaging(Chuzhou)Co.,Ltd. (002969.SZ) announced that the verification process related to its trading suspension has been completed. During the suspension period, the company conducted an investigation into the significant fluctuations in its stock price. As the relevant verification work has now concluded, and in accordance with relevant regulations, the company's stock will resume trading at the market open on January 12, following an application. Between December 17, 2025, and January 6, 2026, the stock price surged by 230.48%, repeatedly triggering abnormal trading volatility alerts. Given the substantial short-term price increase, the company cautioned investors to be mindful of secondary market trading risks. As of the announcement date, Zhuyue Hongzhi has deposited a margin of no less than 20% of the total tender offer consideration (corresponding to 208 million yuan) into a designated bank account with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch. The acquirer, Zhuyue Hongzhi, plans to fund this acquisition using a combination of its own funds and raised capital; however, the application for the raised funds is still pending, and its success remains uncertain. Xianle Health announced that the company is planning to issue H shares and list on the Main Board of The Stock Exchange of Hong Kong Limited. The company will fully consider the interests of existing shareholders and the conditions in both domestic and international capital markets, aiming to select an appropriate timing and issuance window within the validity period of the shareholders' meeting resolution to complete the issuance and listing. On the evening of January 9, CSSC Offshore & Marine Engineering (Group) Company Limited (600685) released its 2025 annual performance forecast, anticipating a net profit attributable to the parent company's owners in the range of 940 million yuan to 1.12 billion yuan. This represents a significant year-on-year increase of 149.61% to 196.88%. On the evening of January 9, Autel Intelligent Technology Corp., Ltd. (688208) announced that it expects its 2025 net profit attributable to the parent company's owners to be between 900 million yuan and 930 million yuan, reflecting a year-on-year growth of 40.42% to 45.10%. After deducting non-recurring gains and losses, the net profit is projected to be between 870 million yuan and 900 million yuan, indicating a robust increase of 60.88% to 66.43%. On the evening of January 9, Huace Navigation (300627) issued a performance forecast, estimating a net profit attributable to the parent company for 2025 of 670 million yuan to 690 million yuan. This would represent a year-on-year growth of 14.84% to 18.27%. On the evening of January 9, Luokai Technology Co., Ltd. (603829) announced that its controlling subsidiary, Fuzhou Yili Electric Equipment Co., Ltd., recently participated in the bidding for the "State Grid Fujian Electric Power 2025 Third Material Framework Inventory Open Tender Procurement" project and was selected as the winning bidder for three product categories. The products involved are high-voltage switchgear, cable branch boxes, and ring main units, with the total value of the contract orders amounting to approximately 48.1959 million yuan. On the evening of January 9, Minhe Co., Ltd. (002234) reported that in December 2025, the company sold 29.6592 million commercial broiler chicks. This figure represents a substantial year-on-year increase of 65.22% and a month-on-month increase of 6.73%. Sales revenue reached 103 million yuan, rising by 53.09% year-on-year and 6.67% month-on-month. The company highlighted that the sales volume of commercial broiler chicks increased by 65.22% year-on-year, while sales revenue climbed by 53.09%. On the evening of January 9, Zhenghai Bio-tech Co., Ltd. (300653) announced that it recently obtained a Medical Device Registration Certificate issued by the National Medical Products Administration. The registered product is a calcium-silicon bioceramic oral bone repair material, which is intended for use in conjunction with a barrier membrane and is suitable for the repair of alveolar bone defects. On the evening of January 9, China Three Gorges Renewables (Group) Co., Ltd. (600905) released a report on its 2025 power generation results. According to preliminary statistics, as of December 31, 2025, the company's total power generation for the fourth quarter of 2025 reached 19.507 billion kWh, a slight increase of 0.92% compared to the same period last year. The cumulative total power generation for the full year 2025 amounted to 76.261 billion kWh, marking a year-on-year growth of 5.99%. On the evening of January 9, Huisheng Biological Co., Ltd. (300871) disclosed its performance forecast, anticipating a net profit attributable to the parent company for 2025 in the range of 235 million yuan to 271 million yuan. This result signifies a turnaround from a net loss of 20.1556 million yuan reported in the same period last year.
Comments